Abbott Thrives Through Knoll Transition; Will Other Firms Follow In 2002?
Executive Summary
Abbott's strong showing on Wall Street in 2001 may be a hopeful sign for the growing group of pharmaceutical companies looking at 2002 as a transition year
You may also be interested in...
Schering Sees Growth Opportunity For Organon Products In The U.S. – Hassan
Schering-Plough sees significant growth potential for Organon's products that currently are marketed in the U.S., CEO Fred Hassan said March 20
Schering Sees Growth Opportunity For Organon Products In The U.S. – Hassan
Schering-Plough sees significant growth potential for Organon's products that currently are marketed in the U.S., CEO Fred Hassan said March 20
Cardinal Manufactures 10% Gain In 1Q: Rx Stocks Stay Out Of Favor
Cardinal's expanding manufacturing capacity is enhancing its image with investors who are attracted to the pharmaceutical sector but wary of the risks of drug development